IL210990A0 - Piperidine derivatives as jak3 inhibitors - Google Patents

Piperidine derivatives as jak3 inhibitors

Info

Publication number
IL210990A0
IL210990A0 IL210990A IL21099011A IL210990A0 IL 210990 A0 IL210990 A0 IL 210990A0 IL 210990 A IL210990 A IL 210990A IL 21099011 A IL21099011 A IL 21099011A IL 210990 A0 IL210990 A0 IL 210990A0
Authority
IL
Israel
Prior art keywords
piperidine derivatives
jak3 inhibitors
jak3
inhibitors
piperidine
Prior art date
Application number
IL210990A
Other languages
English (en)
Original Assignee
Biocryst Pharm Inc
Jan Dare Hatlo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc, Jan Dare Hatlo filed Critical Biocryst Pharm Inc
Publication of IL210990A0 publication Critical patent/IL210990A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL210990A 2008-08-01 2011-02-01 Piperidine derivatives as jak3 inhibitors IL210990A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8570508P 2008-08-01 2008-08-01
US9856208P 2008-09-19 2008-09-19
PCT/US2009/052449 WO2010014930A2 (en) 2008-08-01 2009-07-31 Therapeutic agents

Publications (1)

Publication Number Publication Date
IL210990A0 true IL210990A0 (en) 2011-04-28

Family

ID=41170025

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210990A IL210990A0 (en) 2008-08-01 2011-02-01 Piperidine derivatives as jak3 inhibitors

Country Status (13)

Country Link
US (1) US20110165183A1 (cg-RX-API-DMAC7.html)
EP (1) EP2324020A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011529918A (cg-RX-API-DMAC7.html)
KR (1) KR20110050654A (cg-RX-API-DMAC7.html)
CN (1) CN102171211A (cg-RX-API-DMAC7.html)
AU (1) AU2009276420A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916931A2 (cg-RX-API-DMAC7.html)
CA (1) CA2732628A1 (cg-RX-API-DMAC7.html)
IL (1) IL210990A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011001259A (cg-RX-API-DMAC7.html)
NZ (1) NZ590922A (cg-RX-API-DMAC7.html)
RU (1) RU2011105768A (cg-RX-API-DMAC7.html)
WO (1) WO2010014930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014817A1 (en) 2009-07-31 2011-02-03 Biocryst Pharmaceuticals, Inc. Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors
US20130071415A1 (en) * 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
JP2014513728A (ja) * 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
LT3181567T (lt) 2012-09-10 2019-07-25 Principia Biopharma Inc. Pirazolpirimidino junginiai kaip kinazės slopikliai
AU2013348217B2 (en) * 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
EP2935216B1 (en) * 2012-12-17 2018-06-27 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
WO2014102826A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PT3539965T (pt) * 2013-12-09 2021-04-07 Unichem Lab Ltd Processo melhorado para a preparação de (3r,4r)-(1-benzil-4-metilpiperidin-3-il)-metilamina
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
CN104860950A (zh) * 2014-02-24 2015-08-26 重庆医药工业研究院有限责任公司 一种制备4-氯吡咯[2,3-d]并嘧啶的方法
CN104059016A (zh) * 2014-06-20 2014-09-24 湖南天地恒一制药有限公司 制备托法替布的中间体及所述中间体的制备方法
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
CN107709327A (zh) 2015-06-22 2018-02-16 小野药品工业株式会社 Brk抑制性化合物
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法
CN109600989B (zh) 2016-06-29 2022-11-04 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
JP7710223B2 (ja) 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
KR20220080179A (ko) 2019-10-14 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
CN116768908B (zh) * 2022-03-10 2025-11-18 石家庄迪斯凯威医药科技有限公司 一种含n多环化合物及其制备方法与用途
CN117164519A (zh) * 2023-08-18 2023-12-05 杭州小蓓医药科技有限公司 一种l-肌肽的合成方法
CN117534603A (zh) * 2023-11-10 2024-02-09 江苏海悦康医药科技有限公司 一种托法替布中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
SK287188B6 (sk) * 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP2006509000A (ja) * 2002-11-26 2006-03-16 ファイザー・プロダクツ・インク 移植片拒絶反応の処置の方法
KR100824193B1 (ko) * 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
MXPA06005882A (es) * 2003-11-25 2006-06-27 Pfizer Prod Inc Metodo de tratamiento de la aterosclerosis.
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
PH12013500661A1 (en) * 2010-10-08 2017-08-23 Abbvie Inc FURO[3,2-d]PYRIMIDINE COMPOUNDS

Also Published As

Publication number Publication date
AU2009276420A1 (en) 2010-02-04
CN102171211A (zh) 2011-08-31
KR20110050654A (ko) 2011-05-16
US20110165183A1 (en) 2011-07-07
JP2011529918A (ja) 2011-12-15
NZ590922A (en) 2012-09-28
WO2010014930A3 (en) 2010-07-29
RU2011105768A (ru) 2012-09-10
MX2011001259A (es) 2011-03-15
CA2732628A1 (en) 2010-02-04
EP2324020A2 (en) 2011-05-25
BRPI0916931A2 (pt) 2015-11-24
WO2010014930A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
IL210990A0 (en) Piperidine derivatives as jak3 inhibitors
HRP20180552T1 (hr) Derivati piperidin-4-il azetidina kao inhibitori jak1
IL201073A0 (en) Pyrrolopyrimidine derivatives as jak3 inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL211291A0 (en) Picolinamide derivatives as kinase inhibitors
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
IL210292A0 (en) Heteroaryl derivatives as dgat1 inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
PL2297115T3 (pl) Pochodne di-alkoksychinazolin jako inhibitory receptora KDR
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL208467A0 (en) 3,4-substituted piperidine derivatives as renin inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
IL207315A0 (en) Piperidine derivative
ZA201007486B (en) 3,4- substituted piperidine derivatives as renin inhibitors